Navigation Links
Stryker Operating Results for Quarter Ended September 30, 2009
Date:10/20/2009

KALAMAZOO, Mich., Oct. 20 /PRNewswire-FirstCall/ -- Stryker Corporation (NYSE: SYK) reported operating results for the quarter ended September 30, 2009 as follows:

Third Quarter Highlights

  • Net sales of $1,653 million increased 1.2% on a constant currency basis (flat as reported)
  • Orthopaedic Implants sales increased 6.9% on a constant currency basis (5.5% increase as reported)
  • MedSurg Equipment sales decreased 6.7% on a constant currency basis (7.7% decrease as reported)
  • Recorded restructuring charges of $48 million (net of income tax benefits)
  • Adjusted net earnings increased 1.3% from $274 million to $277 million and adjusted diluted net earnings per share increased 4.5% from $0.66 to $0.69
  • Reported net earnings decreased 16.4% from $274 million to $229 million and reported diluted net earnings per share decreased 13.6% from $0.66 to $0.57

"We are pleased to deliver solid results in a challenging environment with all of our orthopaedic implant businesses posting accelerated worldwide revenue growth, led by strong performances in the U.S. In addition, both our Endoscopy and Medical franchises showed a modest rebound with sequentially higher sales over the second quarter of 2009 despite continued softness in hospital spending," commented Stephen P. MacMillan, President and Chief Executive Officer.

Net sales were $1,653 million in both the third quarter of 2009 and the third quarter of 2008. On a constant currency basis, net sales increased 1.2% for the third quarter.

Net earnings for the third quarter of 2009 were reduced by $48 million of restructuring charges (net of income tax benefits) related to decisions to terminate certain third-party agent agreements at the Company's EMEA Division, to simplify the organization structure at its Biotech, EMEA, Japan and Canada divisions and to discontinue selling certain products.

Excluding the impact of the 2009 restructuring charges, adjusted net earnings for the third quarter of 2009 were $277 million, representing a 1.3% increase compared to net earnings of $274 million for the third quarter of 2008. Adjusted diluted net earnings per share for the third quarter of 2009 were $0.69, representing a 4.5% increase compared to $0.66 for the third quarter of 2008.

Net earnings for the third quarter of 2009 were $229 million, representing a 16.4% decrease compared to net earnings of $274 million for the third quarter of 2008. Diluted net earnings per share for the third quarter of 2009 were $0.57, representing a 13.6% decrease compared to $0.66 for the third quarter of 2008.

Sales Analysis

Domestic sales were $1,070 million for the third quarter of 2009, representing an increase of 0.2%, as a 7.9% increase in shipments of Orthopaedic Implants was partially offset by an 8.3% decrease in shipments of MedSurg Equipment.

International sales were $584 million for the third quarter of 2009, representing a decrease of 0.3%. On a constant currency basis, international sales increased 3.1% in the third quarter of 2009, as a result of a 5.5% increase in shipments of Orthopaedic Implants partially offset by a 2.3% decrease in shipments of MedSurg Equipment.

Worldwide sales of Orthopaedic Implants were $1,017 million for the third quarter of 2009, representing an increase of 5.5% as reported and 6.9% on a constant currency basis. Worldwide sales of MedSurg Equipment were $637 million for the third quarter of 2009, representing a decrease of 7.7% as reported and 6.7% on a constant currency basis.

Outlook for 2009

The Company projects that adjusted diluted net earnings per share for 2009 will be in the range of $2.90 to $3.00, an increase of 2% to 6% over adjusted diluted net earnings per share of $2.83 in 2008. The financial forecast for 2009 anticipates a constant currency net sales increase in the range of 1.0% to 2.0%. If foreign currency exchange rates hold near September 30, 2009 levels, the Company anticipates a favorable impact on net sales of approximately 3.2% to 4.2% in the fourth quarter of 2009 and an unfavorable impact on net sales of approximately 1.6% to 2.0% for the full year of 2009.

Conference Call

As previously announced, the Company will conduct a conference call for financial analysts at 4:30 p.m., Eastern Time, today. To participate in the conference call dial 800-706-7745 (domestic) or 617-614-3472 (international) and enter the participant passcode 89830336. A simultaneous webcast of the call will be accessible via the Company's website at www.stryker.com. The webcast will be archived on this site for 90 days.

A recording of the call will also be available from 7:30 p.m., Eastern Time, on Tuesday, October 20, 2009, until 7:30 p.m. on Tuesday, October 27, 2009. To hear this recording, dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter the passcode 66937880.

Forward-Looking Statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause the Company's actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: further weakening of economic conditions that could adversely affect the level of demand for the Company's products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for the Company's products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; unfavorable resolution of tax audits; changes in financial markets; and changes in the competitive environment. Additional information concerning these and other factors is contained in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Stryker Corporation is one of the world's leading medical technology companies with the most broadly based range of products in orthopaedics and a significant presence in other medical specialties. Stryker works with respected medical professionals to help people lead more active and more satisfying lives. The Company's products include implants used in joint replacement, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment. For more information about Stryker, please visit www.stryker.com.

                               STRYKER CORPORATION
       For the Three Month and Nine Month Periods Ended September 30, 2009
                (Unaudited - In Millions Except Per Share Amounts)


                                Third Quarter               Nine Months
    CONDENSED STATEMENTS                       %                         %
     OF EARNINGS             2009     2008   Change     2009     2008  Change

      Net sales           $1,653.3 $1,653.0    0.0  $4,888.9 $5,000.0   (2.2)
      Cost of sales          538.7    541.7   (0.6)  1,590.5  1,575.4    1.0


        GROSS PROFIT       1,114.6  1,111.3    0.3   3,298.4  3,424.6   (3.7)
          % of Sales          67.4     67.2             67.5     68.5

      Research,
       development and
       engineering
       expenses               83.7     92.6   (9.6)    246.7    268.0   (7.9)
      Selling, general and
       administrative
       expenses              643.9    644.8   (0.1)  1,877.6  1,977.5   (5.1)
      Intangibles
       amortization            8.6      9.8  (12.2)     26.7     30.4  (12.2)
      Restructuring
       charges                67.0        -      -      67.0        -      -


                             803.2    747.2    7.5   2,218.0  2,275.9   (2.5)


        OPERATING INCOME     311.4    364.1  (14.5)  1,080.4  1,148.7   (5.9)
          % of Sales          18.8     22.0             22.1     23.0


      Other income (expense)   3.0     11.9  (74.8)     20.4     51.4  (60.3)


          EARNINGS BEFORE
           INCOME TAXES      314.4    376.0  (16.4)  1,100.8  1,200.1   (8.3)

      Income taxes            85.4    102.2  (16.4)    299.4    330.0   (9.3)


        NET EARNINGS        $229.0   $273.8  (16.4)   $801.4   $870.1   (7.9)



       Net earnings per
        share
          Basic              $0.58    $0.67  (13.4)    $2.02    $2.12   (4.7)
          Diluted net
           earnings per
           share             $0.57    $0.66  (13.6)    $2.01    $2.09   (3.8)

      Average Shares
       Outstanding
        Basic                397.6    409.7            397.2    411.0
        Diluted              399.6    415.8            399.1    417.2


    RECONCILIATION OF
     REPORTED NET EARNINGS
     TO ADJUSTED NET
     EARNINGS

                                Third Quarter              Nine Months
                                              %                         %
                             2009     2008  Change     2009     2008  Change
    NET EARNINGS
    Reported net
     earnings               $229.0   $273.8  (16.4)   $801.4   $870.1   (7.9)
    Restructuring charges     48.4        -      -      48.4        -      -
    Adjusted net
     earnings               $277.4   $273.8    1.3    $849.8   $870.1   (2.3)

    DILUTED NET EARNINGS
     PER SHARE
    Reported diluted net
     earnings per share      $0.57    $0.66  (13.6)    $2.01    $2.09   (3.8)
    Restructuring charges    $0.12       $-      -     $0.12       $-      -
    Adjusted diluted net
     earnings per share      $0.69    $0.66    4.5     $2.13    $2.09    1.9



                            STRYKER CORPORATION
     For the Three Month and Nine Month Periods Ended September 30, 2009
                         (Unaudited - In Millions)

                                         Third Quarter
                                                      % Change
                                                           Constant
    CONDENSED SALES ANALYSIS    2009     2008   Reported   Currency

      Domestic               $1,069.6 $1,067.8      0.2        0.2
      International             583.7    585.2     (0.3)       3.1


        NET SALES            $1,653.3 $1,653.0      0.0        1.2


      Orthopaedic Implants   $1,016.7   $963.3      5.5        6.9
      MedSurg Equipment         636.6    689.7     (7.7)      (6.7)


        NET SALES            $1,653.3 $1,653.0      0.0        1.2



                                         Nine Months
                                                      % Change
                                                           Constant
    CONDENSED SALES ANALYSIS    2009     2008   Reported   Currency

      Domestic               $3,158.8 $3,153.5      0.2        0.2
      International           1,730.1  1,846.5     (6.3)       3.6


        NET SALES            $4,888.9 $5,000.0     (2.2)       1.4


      Orthopaedic Implants   $3,004.1 $2,950.6      1.8        6.1
      MedSurg Equipment       1,884.8  2,049.4     (8.0)      (5.2)


        NET SALES            $4,888.9 $5,000.0     (2.2)       1.4



                                            Third Quarter
                                              % Change
                          Domestic    International          Total
    SUPPLEMENTAL SALES                        Constant            Constant
     GROWTH ANALYSIS      Reported  Reported  Currency  Reported  Currency

    Orthopaedic
     Implants sales:
      Hips                       7         1         5         4         6
      Knees                     10        (3)        1         5         7
      Trauma                     6         5         6         5         6
      Spine                     13        14        16        14        14
      Craniomaxillofacial       12         9        12        11        12
      Total Orthopaedic
       Implants                  8         2         5         6         7

    MedSurg Equipment sales:
      Surgical equipment
       and surgical
       navigation systems        3         1         5         2         3
      Endoscopic,
       communications and
       digital imaging
       systems                 (10)       11        16        (5)       (4)
      Patient handling
       and emergency
       medical equipment       (23)      (45)      (43)      (28)      (27)
      Total MedSurg Equipment   (8)       (6)       (2)       (8)       (7)


                                             Nine Months
                                              % Change
                          Domestic    International          Total
                                              Constant            Constant
                          Reported  Reported  Currency  Reported  Currency

    Orthopaedic
     Implants sales:
      Hips                       6        (6)        5         0         6
      Knees                     10       (10)        1         2         6
      Trauma                     9        (2)        4         2         6
      Spine                     13         4        12        10        13
      Craniomaxillofacial       12        (9)        1         5         8
      Total Orthopaedic
       Implants                  8        (6)        4         2         6

    MedSurg Equipment sales:
      Surgical equipment
       and surgical
       navigation systems        3        (8)        2         0         3
      Endoscopic,
       communications and
       digital imaging
       systems                  (8)        1        13        (6)       (3)
      Patient handling
       and emergency
       medical equipment       (27)      (24)      (14)      (26)      (24)
      Total MedSurg Equipment   (8)       (8)        3        (8)       (5)



                           STRYKER CORPORATION
                        (Unaudited - In Millions)


                                              September 30  December 31
    CONDENSED BALANCE SHEETS                      2009         2008

      ASSETS

      Cash and cash equivalents                   $960.3      $701.1

      Marketable securities                      1,969.1     1,494.5

      Accounts receivable (net)                  1,113.5     1,129.5

      Inventories                                  977.3       952.7

      Other current assets                         741.6       701.5

        TOTAL CURRENT ASSETS                     5,761.8     4,979.3

      Property, Plant and Equipment (net)          954.1       963.8

      Goodwill and Other Intangibles (net)         954.9       935.5

      Other Assets                                 788.4       724.7

        TOTAL ASSETS                            $8,459.2    $7,603.3


      LIABILITIES AND SHAREHOLDERS' EQUITY

      Current Liabilities                       $1,198.0    $1,462.1

      Other Liabilities                            820.3       734.5

      Shareholders' Equity                       6,440.9     5,406.7

        TOTAL LIABILITIES AND
         SHAREHOLDERS' EQUITY                   $8,459.2    $7,603.3



                               STRYKER CORPORATION
       For the Three Month and Nine Month Periods Ended September 30, 2009
                            (Unaudited - In Millions)


                                              Third Quarter    Nine Months
    CONDENSED STATEMENTS OF CASH FLOWS         2009    2008    2009    2008

      OPERATING ACTIVITIES

      Net earnings                           $229.0  $273.8  $801.4  $870.1

      Depreciation                             41.1    39.5   117.9   118.0

      Amortization                             55.5    58.1   162.6   176.5

      Restructuring charges                    67.0       -    67.0       -

      Changes in working capital and other     73.2   (45.9) (228.3) (408.0)

        NET CASH PROVIDED BY OPERATING
         ACTIVITIES                           465.8   325.5   920.6   756.6


      INVESTING ACTIVITIES

      Acquisitions, net of cash acquired       (6.0)   (2.2)  (17.7)  (10.8)

      Proceeds from (purchases of)
       marketable securities, net            (146.3)  545.1  (397.8)  434.6

      Purchases of property, plant and
       equipment                              (28.6)  (37.0)  (89.6) (109.1)

      Proceeds from sales of property,
       plant and equipment                      0.6     0.2     1.5     0.4


        NET CASH PROVIDED BY (USED IN)
         INVESTING ACTIVITIES                (180.3)  506.1  (503.6)  315.1


      FINANCING ACTIVITIES

      Borrowings (repayments) of debt, net     (1.9)   (1.2)   (2.8)    5.9

      Dividends paid                              -       -  (158.6) (135.6)

      Repurchase and retirement of common
       stock                                      -  (596.0)      -  (596.0)

      Other                                   (17.1)   39.7   (17.9)   44.7

        NET CASH USED IN FINANCING
         ACTIVITIES                           (19.0) (557.5) (179.3) (681.0)

      Effect of exchange rate changes on
       cash and cash equivalents               27.5   (27.7)   21.5   (13.2)

        CHANGE IN CASH AND CASH EQUIVALENTS  $294.0  $246.4  $259.2  $377.5

SOURCE Stryker Corporation


'/>"/>
SOURCE Stryker Corporation
Copyright©2009 PR Newswire.
All rights reserved


Related medicine technology :

1. Strykers Biotech Division Receives FDA Warning Letter
2. Methodist Hospital Adopts New Technology Solutions to Improve Care for California Patients and Reduce Operating Costs
3. LifeVantage Announces Fourth Quarter and Fiscal Year 2009 Financial and Operating Results
4. Amylin Pharmaceuticals Reports Third Quarter Financial Results
5. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
6. IPC The Hospitalist Company, Inc. to Report Third Quarter 2009 Results
7. Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009
8. Masimo to Report Third Quarter 2009 Financial Results on November 3, 2009
9. AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
10. 3SBio Inc. Announces Results of Annual General Meeting
11. Boston Scientific Announces Results for Third Quarter Ended September 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, households ... mail from USA Medical Prescription Assistance Program. They are customized to reflect the ... package will include a ready-to-use, state-themed card and, in the near future, material ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in Motion Coalition ... an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and data collection. ... 1, 2016. , Sarcopenia is defined as a combination of low muscle mass and ...
(Date:4/28/2016)... ... April 28, 2016 , ... North Hollywood dentist , Dr. Hamid ... is essential when it comes to dental accidents or critical dental problems. These issues ... losing a tooth. Toothaches, knocked-out teeth, chipped teeth, and many other issues can lead ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... an invitation to those affected by a health insurance co-operative bankruptcy to ... proprietary process, individuals can receive over 1,500 FDA-approved prescription medications from over ...
(Date:4/28/2016)... , ... April 28, 2016 , ... For many, a diet is only as good ... if it does not look good. In addition, an individual cannot deny the importance of ... , The team, therefore, has worked to create a product range that could entice people ...
Breaking Medicine News(10 mins):